Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.
Författare
Summary, in English
Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.
Avdelning/ar
Publiceringsår
2015
Språk
Engelska
Sidor
10-10
Publikation/Tidskrift/Serie
BMC Hematology
Volym
15
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
BioMed Central (BMC)
Ämne
- Hematology
Status
Published
ISBN/ISSN/Övrigt
- ISSN: 2052-1839